OpenAlex 1,608 works 6 author topics
Works
1,608 works
-
YÖKSİS
SJR Q1
JCR Q1
OpenAlex top 1%
OpenAlex 100.0%
No abstract yet.
-
YÖKSİS
SJR Q1
JCR Q1
OpenAlex top 1%
OpenAlex 100.0%
Recent advances in human genetics, together with a large body of epidemiologic, preclinical, and clinical trial results, provide strong support for a causal association between triglycerides (TG), TG-rich lipoproteins (TRL), and TRL remnants, and increased risk of myocardial infarction, ischaemic stroke, and aortic va…
-
YÖKSİS
SJR Q2
JCR Q3
OpenAlex top 10%
OpenAlex 96.6%
Atherosclerotic cardiovascular disease (ASCVD) is the leading cause of death and it has been confirmed that increased low density lipoprotein cholesterol (LDL-C) is an independent risk factor for atherosclerosis. Recently, the increasing evidence has showed that hypertriglyceridemia is associated with incremental ASCV…
-
YÖKSİS
SJR Q1
JCR Q1
OpenAlex top 1%
OpenAlex 99.8%
Combination lipid-lowering therapy as first line strategy in very high-risk patients. Combination lipid-lowering therapy as first line strategy in very high-risk patients.
-
YÖKSİS
SJR Q1
JCR Q1
OpenAlex top 1%
OpenAlex 99.6%
No abstract yet.
-
YÖKSİS
SJR Q1
JCR Q1
OpenAlex top 1%
OpenAlex 99.8%
BACKGROUND: Evolocumab, a fully human monoclonal antibody directed against proprotein convertase subtilisin-kexin type 9, is widely used in adult patients to lower low-density lipoprotein (LDL) cholesterol levels. Its effects in pediatric patients with heterozygous familial hypercholesterolemia are not known. METHODS:…
-
YÖKSİS
OpenAlex top 1%
OpenAlex 99.7%
Lipid risk factors for cardiovascular disease depend in part on lifestyle, but optimum control of lipids often demands additional measures. Low-density lipoprotein (LDL) doubtless contributes causally to atherosclerosis. Recent human genetic findings have substantiated a number of novel targets for lipid-lowering ther…
-
YÖKSİS
SJR Q2
JCR Q3
OpenAlex top 10%
OpenAlex 92.5%
No abstract yet.
-
YÖKSİS
SJR Q2
JCR Q3
OpenAlex top 10%
OpenAlex 92.5%
No abstract yet.
-
YÖKSİS
SJR Q2
JCR Q3
OpenAlex top 10%
OpenAlex 92.5%
No abstract yet.
-
YÖKSİS
SJR Q2
JCR Q3
OpenAlex top 10%
OpenAlex 92.5%
No abstract yet.
-
OpenAlex top 10%
OpenAlex 94.4%
In recent years, there has been renewed interest in hematological parameters as predictors of endothelial dysfunction and inflammation. The aim of our study is to evaluate the relationship between HbA1c and hematological indices, and to evaluate the relationship between these parameters and microvascular complications…
Academicians
6 academicians